ADAP vs. MGX, IVVD, CRBU, BDTX, PSTX, CHRS, ZURA, IPHA, AGEN, and SOPH
Should you be buying Adaptimmune Therapeutics stock or one of its competitors? The main competitors of Adaptimmune Therapeutics include Metagenomi (MGX), Invivyd (IVVD), Caribou Biosciences (CRBU), Black Diamond Therapeutics (BDTX), Poseida Therapeutics (PSTX), Coherus BioSciences (CHRS), Zura Bio (ZURA), Innate Pharma (IPHA), Agenus (AGEN), and SOPHiA GENETICS (SOPH). These companies are all part of the "biological products, except diagnostic" industry.
Adaptimmune Therapeutics (NASDAQ:ADAP) and Metagenomi (NASDAQ:MGX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk.
Metagenomi has lower revenue, but higher earnings than Adaptimmune Therapeutics.
Adaptimmune Therapeutics received 299 more outperform votes than Metagenomi when rated by MarketBeat users. However, 90.00% of users gave Metagenomi an outperform vote while only 62.47% of users gave Adaptimmune Therapeutics an outperform vote.
31.4% of Adaptimmune Therapeutics shares are owned by institutional investors. 12.4% of Adaptimmune Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Adaptimmune Therapeutics currently has a consensus target price of $2.67, suggesting a potential upside of 160.16%. Metagenomi has a consensus target price of $17.83, suggesting a potential upside of 179.96%. Given Metagenomi's stronger consensus rating and higher probable upside, analysts clearly believe Metagenomi is more favorable than Adaptimmune Therapeutics.
In the previous week, Adaptimmune Therapeutics had 1 more articles in the media than Metagenomi. MarketBeat recorded 3 mentions for Adaptimmune Therapeutics and 2 mentions for Metagenomi. Metagenomi's average media sentiment score of 1.25 beat Adaptimmune Therapeutics' score of 0.94 indicating that Metagenomi is being referred to more favorably in the news media.
Metagenomi has a net margin of 0.00% compared to Adaptimmune Therapeutics' net margin of -890.13%. Metagenomi's return on equity of 0.00% beat Adaptimmune Therapeutics' return on equity.
Summary
Metagenomi beats Adaptimmune Therapeutics on 10 of the 15 factors compared between the two stocks.
Get Adaptimmune Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADAP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ADAP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Adaptimmune Therapeutics Competitors List
Related Companies and Tools
